Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
Coronavirus Infection
Interventions
BIOLOGICAL

Plasma

The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.

OTHER

Best Available Therapy

It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.

Trial Locations (1)

64460

Hospital Universitario José E. Gonzalez, Monterrey

All Listed Sponsors
lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

NCT04358783 - Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia | Biotech Hunter | Biotech Hunter